Project Details
Description
A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-255 AS A SINGLE AGENT IN RELAPSED OR REFRACTORY HEMATOLOGICAL MALIGNANCIES AND IN COMBINATION WITH DARATUMUMAB AS A SALVAGE REGIMEN FOR MULTIPLE MYELOMA
| Status | Finished |
|---|---|
| Effective start/end date | 12/2/19 → 12/31/24 |
Funding
- NEKTAR THERAPEUTICS
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.